These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24063417)

  • 1. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.
    Harada N; Kimura H; Ono M; Saji H
    J Med Chem; 2013 Oct; 56(20):7890-901. PubMed ID: 24063417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
    Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
    Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of succinimidyl-Cys-C(O)-Glu derivatives with different near-infrared fluorophores as optical imaging probes for prostate-specific membrane antigen.
    Matsuoka D; Watanabe H; Shimizu Y; Kimura H; Yagi Y; Kawai R; Ono M; Saji H
    Bioorg Med Chem; 2018 May; 26(9):2291-2301. PubMed ID: 29580851
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
    Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of a novel near-infrared fluorescent probe based on succinimidyl-Cys-C(O)-Glu that targets prostate-specific membrane antigen for optical imaging.
    Matsuoka D; Watanabe H; Shimizu Y; Kimura H; Ono M; Saji H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4876-4880. PubMed ID: 28964633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
    Hillier SM; Kern AM; Maresca KP; Marquis JC; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2011 Jul; 52(7):1087-93. PubMed ID: 21680691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
    Kimura H; Sampei S; Matsuoka D; Harada N; Watanabe H; Arimitsu K; Ono M; Saji H
    Bioorg Med Chem; 2016 May; 24(10):2251-6. PubMed ID: 27073053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
    Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
    J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
    Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
    Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer.
    Graham K; Lesche R; Gromov AV; Böhnke N; Schäfer M; Hassfeld J; Dinkelborg L; Kettschau G
    J Med Chem; 2012 Nov; 55(22):9510-20. PubMed ID: 23025786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y; Ando M; Watanabe H; Ono M
    Ann Nucl Med; 2024 Oct; 38(10):847-851. PubMed ID: 38976087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine-based asymmetric urea ligand for prostate carcinoma: Tuning biological efficacy through in silico studies.
    Sengupta S; Krishnan MA; Pandit A; Dudhe P; Sharma R; Chelvam V
    Bioorg Chem; 2019 Oct; 91():103154. PubMed ID: 31404798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.